Prognostic relevance of CD163⁺ immune cells in patients with metastatic breast cancer.

ABSTRACT: Metastatic breast cancer (MBC) is generally considered an incurable disease and even though new treatments are available, the median survival is approximately three years. The introduction of immune therapies for MBC highlights the importance of the immune system in cancer progression and treatment. CD163⁺ anti-inflammatory myeloid cells, including tumor associated macrophages (TAMs), are known to be of relevance in early breast cancer but their role in MBC is not yet established. Here we determine the levels of CD163⁺ immune cells in 139 patients with newly diagnosed MBC by using Immunohistochemistry (IHC) and gene expression analyses (GEX). We aim to determine changes and distribution of CD163⁺ immune cells during tumor progression from primary tumors (PT

SUBMITTER: Lindberg I 

PROVIDER: S-EPMC11699000 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature